問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃釧峰

Recruiting

List

56Cases

2023-09-01 - 2027-04-30

Phase II

Active
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Budigalimab (ABBV-181)；Livmoniplimab (ABBV-151)

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2025-09-23 - 2028-02-13

Phase II

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic hepatitis B virus (HBV) infection

  • Test Drug

    Film-coated tablet Film-coated tablet

Participate Sites
8Sites

Recruiting8Sites

2024-11-01 - 2028-06-30

Phase II

Active
A Phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with daplusiran/tomligisiran followed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy (B-United)

  • Condition/Disease

    chronic hepatitis B

  • Test Drug

    Daplusiran/Tomligisiran (GSK5637608) Bepirovirsen (GSK3228836)

Participate Sites
4Sites

Recruiting4Sites

2022-01-01 - 2025-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2023-01-05 - 2026-12-13

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-12-01 - 2022-12-31

Phase II

Completed
A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract Cancer

  • Condition/Disease

    Advanced Biliary Tract Cancer

  • Test Drug

    OPDIVO

Participate Sites
7Sites

Recruiting7Sites

2024-06-11 - 2030-12-31

Phase III

Active
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    靜脈點滴注射劑

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2024-11-15 - 2032-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-10-15 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-03-01 - 2028-12-31

Phase III

Active
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

  • Condition/Disease

    Incurable/Non-metastatic Hepatocellular Carcinoma

  • Test Drug

    Pembrolizumab (Keytruda)； Lenvatinib (Lenvima)

Participate Sites
8Sites

Recruiting4Sites

Terminated4Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB